STAT
FEBRUARY 7, 2024
In recent months, the federal government has repeatedly told Medicare Advantage insurers that they cannot use artificial intelligence or algorithms to deny medical services the government routinely covers. But in finalizing a rule to that effect, it also stepped into a thicket of questions from insurers about a technology that is especially difficult to pin down: What is AI?
PharmaVoice
FEBRUARY 7, 2024
Investment heavyweights BlackRock and Glass Lewis want compensation clawbacks on execs who don’t protect a company’s reputation.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
FEBRUARY 7, 2024
Fatigue leads the list of persistent problems experienced by people with long Covid — which is why patients have pushed back against treatment approaches that endorse escalating levels of exercise for a condition that researchers are still trying to understand. They fear post-exertional malaise, the debilitating price to be paid for pushing their bodies too hard.
The Pharmacist
FEBRUARY 7, 2024
Using Additional Roles Reimbursement Scheme (ARRS) funding for GPs would be ‘ridiculous’ given the difficulty of recruiting doctors and the efficiency of utilising other roles within the surgery, a pharmacist partner in a south coast general practice has said. Shilpa Patel, lead prescribing pharmacist and partner at WellBN health centre in Brighton and Hove, spoke […] The post Adding GPs to ARRS not the way forward, says pharmacist partner appeared first on The Pharmacist.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
FEBRUARY 7, 2024
David Reese calls it a “hinge moment” — the turning point when biotech and big tech merge to attack human disease with artificial intelligence. At Amgen, where he’s led drug research and development since 2018, Reese said this moment has finally arrived. The proof lies not only in organizational changes, such as his recent appointment as the company’s first chief technology officer, but also in Amgen’s broader push to embed AI into every aspect of the dr
BioPharma Dive
FEBRUARY 7, 2024
The new firm intends to carefully select its startups and fund them for the long haul. “We're not a company formation factory,” said Aaron Kantoff, the firm’s co-founder.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
FDA Law Blog: Biosimilars
FEBRUARY 7, 2024
By John A. Gilbert — Last week, DEA and DOJ announced a $59 million civil penalty settlement with eBay related to the failure to comply with Controlled Substances Act (CSA) requirements for identifying purchasers, maintaining records, and filing reports of individuals selling/purchasing pill presses and encapsulating machines. As stated in the press release , this was the fourth largest civil penalty settlement under the CSA and, ironically, did not involve the sale or distribution of any contr
STAT
FEBRUARY 7, 2024
In the clinical trial, the gene therapy seemed to be helping the boy’s skin wounds heal. But, his doctors wondered, could it also help his eyes? The boy, Antonio Vento Carvajal, had a genetic condition called epidermolysis bullosa, or EB, which causes the skin to be so fragile that even the slightest friction can cause blisters or tears. Antonio, like some patients, also had eye issues as a result of the disease.
pharmaphorum
FEBRUARY 7, 2024
Stay updated on the latest clinical trials happening from January 15th to January 19th, 2024. Explore trials by ExeVir, NurixTx, Synendos Therapeutics, and Oxford BioTx.
STAT
FEBRUARY 7, 2024
Amid ongoing concern over opioid addiction, a university in Florida has been criticized for allowing a lecture that conveyed “false and misleading” information about the use of the prescription painkillers by a local physician who, in years past, had ties to opioid makers. At issue was a lecture that was given last October at Nova Southeastern University in Fort Lauderdale, Fla., by Martin Hale, an orthopedic surgeon, to first-year medical students about managing pain.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
FEBRUARY 7, 2024
Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma, continuing a move into targeted cancer therapies. Under the terms of the deal, Jazz will acquire Redx’s KRAS inhibitor programme outright, including multiple preclinical-stage drug candidates, and will take responsibility for ushering the most promising compounds through clinical trials and onto the market.
STAT
FEBRUARY 7, 2024
Three biotech VC veterans, including one of the co-founders of radiopharma success story RayzeBio, are launching a new investment fund called Scion Life Sciences. Scion was started by former Apple Tree Partners colleagues Sam Hall and Aaron Kantoff, along with Tadd Wessel, managing partner of the health care private equity firm Petrichor. They raised $310 million for its first fund, blowing past their original $250 million target.
pharmaphorum
FEBRUARY 7, 2024
As the pandemic recedes and the global economy stabilises, are there promising signs for the biotech industry's financial outlook in 2024? Learn more about the potential for recovery, reducing bankruptcies, and attracting investors.
STAT
FEBRUARY 7, 2024
Rise and shine, everyone. The middle of the week is upon us. Have heart, though. You made it this far, so why not hang on for another couple of days, yes? Consider the alternatives, if you must. And what better way to make the time fly than to keep busy. So grab that cup of stimulation — our flavor today is maple bourbon — and get started.
pharmaphorum
FEBRUARY 7, 2024
In this interview, Simon Arkell, co-founder and CEO of Ryght, discusses his vision whilst at JP Morgan 2024 and how generative AI is transforming the industry.
STAT
FEBRUARY 7, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, all. Damian here with news of a new biotech venture fund, a bold bet against a billion-dollar deal, and the weight of expectations on Eli Lilly.
pharmaphorum
FEBRUARY 7, 2024
GSK has revealed the data it hopes will allow a return to the US market for Blenrep, which was the first BCMA-targeting drug to launch there but was withdrawn from sale after it failed a confirmatory trial.
STAT
FEBRUARY 7, 2024
As leaders across federal agencies swiftly advance regulations for AI in health care, one proposal now seems too big to fail. That proposal is for the implementation of AI assurance laboratories — places where AI model developers can develop and test AI models according to standard criteria that would be defined with regulators.
Pharma Times
FEBRUARY 7, 2024
The HTA reported that Brainomix 360 improved access to treatment for stroke patients
Drug Channels
FEBRUARY 7, 2024
The boffins at the Centers for Medicare & Medicaid Services (CMS) recently dropped the latest National Health Expenditure (NHE) data, which measures all U.S. spending on healthcare. (Links below.) As you will see, retail and mail prescription drug spending remain a consistently small share of the $4.5 trillion that we spend on U.S. healthcare. And contrary to what you might read, drug spending growth was *not* driven by purportedly “skyrocketing” drug prices.
Outsourcing Pharma
FEBRUARY 7, 2024
Wedneday is Women in Science day and we have a fantastic interview with Hella who is co-founder and chief scientific officer of Immunic Therapeutics.
Express Pharma
FEBRUARY 7, 2024
Following the news that Novo Holdings, the parent company to Novo Nordisk, has agreed to acquire contract development and manufacturing organisation (CDMO) Catalent for $16.5 billion; Costanza Alciati, Pharma Analyst at GlobalData, offers her view: “ Novo Nordisk has been struggling to meet the demand related to its GLP-1R agonists products, notably Ozempic and Wegovy, approved for type 2 diabetes and obesity respectively.
The Pharmacist
FEBRUARY 7, 2024
An influential report by The Times Health Commission has proposed new community health centres as well as GP ‘super-practices’ to house multi-disciplinary healthcare teams, including pharmacists. It also suggested that pharmacists could play a greater role in medicines optimisation and safety, reducing pressure on hospitals and saving the NHS money.
World Pharma News
FEBRUARY 7, 2024
Vividion Therapeutics, Inc. (Vividion), announced that it has initiated dosing of patients in a Phase I clinical trial evaluating VVD-130850, an investigational oral STAT3 inhibitor for the treatment of advanced solid and hematologic tumors.
Express Pharma
FEBRUARY 7, 2024
Looking ahead to the next five years, the pharma industry, once a significant greenhouse gas emitter, is set to undergo substantial growth and transformation in response to the urgent call for sustainability. The sector is making remarkable strides, evident in its pivotal role in the Indian government’s National Action Plan on Climate Change (NAPCC).
BioPharma Dive
FEBRUARY 7, 2024
The company, a leading developer of cell therapies for autoimmune diseases, is the fifth drug startup to go public in 2024. All of them raised at least $100 million.
pharmaphorum
FEBRUARY 7, 2024
Eli Lilly has called on financial regulators to look into the antitrust implications of Novo Holdings purchase of Catalent and the sale of three manufacturing facilities to Novo Nordisk.
Pharmaceutical Technology
FEBRUARY 7, 2024
AstraZeneca is investing $300m in a facility in Rockville, US - a significant step in launching its cell therapy platforms in the country.
European Pharmaceutical Review
FEBRUARY 7, 2024
AstraZeneca has announced a $300 million investment in a US-based manufacturing facility in Rockville, Maryland, which will focus initially on T-cell therapies for oncology indications. The site will launch the company’ s cell therapy platforms in the US for critical cancer trials and future commercial supply. The site may widen its focus to support other disease areas, according to AstraZeneca.
pharmaphorum
FEBRUARY 7, 2024
Jewish people in England are being asked to have gene testing for BRCA mutations that elevate their risk of breast cancer
Pharma Times
FEBRUARY 7, 2024
The new products are in the areas of gastrointestinal and respiratory medicines
Pharmaceutical Technology
FEBRUARY 7, 2024
Gilead Sciences has announced a 22.9% increase in net income of $5.61bn for FY23 as against $4.56bn in FY22.
The Guardian - Pharmaceutical Industry
FEBRUARY 7, 2024
Britain is pushing for patent changes that could increase the cost of Indian generic drugs, diverting more of the NHS budget to big pharma India is known as the “ pharmacy of the world ”, supplying vital generic medicines at low prices to health services including the NHS. You’d think it would be in the interest of the UK government to keep it that way.
Pharmaceutical Technology
FEBRUARY 7, 2024
BCMA-GPRC5D CAR-T Cells is under clinical development by Guangzhou Bio-gene Technology and currently in Phase II for Relapsed Multiple Myeloma.
Drug Patent Watch
FEBRUARY 7, 2024
Annual Drug Patent Expirations for APONVIE Aponvie is a drug marketed by Heron Theraps Inc and is included in one NDA. It is available from one supplier. There are ten… The post New patent for Heron Theraps drug APONVIE appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
360 
Let's personalize your content